2. Five-Year Long-Term Follow-Up

A 324-patient cohort from the initial trial was monitored for five years.

• activL maintained noninferior outcomes compared to earlier-generation discs.

• Range of motion was significantly better in activL patients.

• Freedom from serious adverse events at five years favored activL: 64% vs. 47% (P = 0.0068).

• Reoperation rates remained high: 94–99% avoiding index or adjacent segment surgery.

(Source: PubMed)

3. Additional Long-Term Data

Seven-year results from the IDE trial are available, reinforcing sustained clinical and radiographic performance for activL.

A separate Med Devices review (2016) described activL as a “next-generation motion-preserving implant” designed to optimize segmental stability and longevity.

(Source: PubMed)

Cautions and Context

• Level 2 evidence: While trials are robust (randomized, multicenter), they are not blinded.

• Patient selection matters: Ideal candidates are single-level DDD after failed conservative care.

• Need for real-world data: Broader use, including multi-level cases and registry data, is limited.

• Surgeon experience: Successful outcomes rely heavily on technique and surgical training.

Bottom Line

activL® lumbar disc is backed by high-quality data showing:

• Equivalent or superior pain relief and function to established lumbar discs

• Enhanced range of motion

• Lower serious adverse events over mid-term

• Durable results through 5+ years with low reintervention rates

However, these findings come from controlled studies. For widespread real-world acceptance, longitudinal registries, broader patient cohorts, and post-market data will be critical. Future reporting, especially from Highridge’s clinical development, should be closely monitored.